Modulation by Endothelin-1 of Spontaneous Activity and Membrane Currents of Atrioventricular Node Myocytes from the Rabbit Heart

Stéphanie C. Choisy¹, Hongwei Cheng¹, Godfrey L. Smith², Andrew F. James¹*️, Jules C. Hancox¹*

¹ School of Physiology & Pharmacology, Medical Sciences Building, University of Bristol, Bristol, United Kingdom, ²Cardiovascular Physiology, University of Glasgow, Glasgow, United Kingdom

Abstract

**Background:** The atrioventricular node (AVN) is a key component of the cardiac pacemaker-conduction system. Although it is known that receptors for the peptide hormone endothelin-1 (ET-1) are expressed in the AVN, there is very little information available on the modulatory effects of ET-1 on AVN electrophysiology. This study characterises for the first time acute modulatory effects of ET-1 on AVN cellular electrophysiology.

**Methods:** Electrophysiological experiments were conducted in which recordings were made from rabbit isolated AVN cells at 35–37 °C using the whole-cell patch clamp recording technique.

**Results:** Application of ET-1 (10 nM) to spontaneously active AVN cells led rapidly (within ~13 s) to membrane potential hyperpolarisation and cessation of spontaneous action potentials (APs). This effect was prevented by pre-application of the ETA receptor inhibitor BQ-123 (1 μM) and was not mimicked by the ETB receptor agonist IRL-1620 (300 nM). In whole-cell voltage-clamp experiments, ET-1 partially inhibited L-type calcium current (I_{Ca,L}) and rapid delayed rectifier K⁺ current (I_K), whilst it transiently activated the hyperpolarisation-activated current (I_h) at voltages negative to the pacemaking range, and activated an inwardly rectifying current that was inhibited by both tertiapin-Q (300 nM) and Ba²⁺ ions (2 mM); each of these effects was sensitive to ETA receptor inhibition. In cells exposed to tertiapin-Q, ET-1 application did not produce membrane potential hyperpolarisation or immediate cessation of spontaneous activity; instead, there was a progressive decline in AP amplitude and depolarisation of maximum diastolic potential.

**Conclusions:** Acutely applied ET-1 exerts a direct modulatory effect on AVN cell electrophysiology. The dominant effect of ET-1 in this study was activation of a tertiapin-Q sensitive inwardly rectifying K⁺ current via ETA receptors, which led rapidly to cell quiescence.

Introduction

The atrioventricular node (AVN) is a small yet critically important component of the cardiac pacemaker-conduction system that lies at the junction between right atrium and ventricle [1,2]. It is normally the only site where electrical activity can pass from atria to ventricles [1,2]. Comparatively slow conduction through the AVN co-ordinates the normal timing of atrial then ventricular excitation [2,3] and in the setting of supraventricular tachycardias such as atrial fibrillation, this limits impulse transmission to the ventricles [2,4]. On the other hand, aberrant AVN conduction can itself lead to arrhythmia [2,5]. The AVN also has pacemaking properties [2,5]. Normally these are subordinate to the heart's dominant pacemaker the sinoatrial node (SAN); however, should the SAN fail the AVN can take over pacemaking of the ventricles [2,5]. AVN pacemaking is incompletely understood, but is established to involve an interplay between the activity of a number of different ionic conductances [6–10].

Endothelin-1 (ET-1) is a potent vasoactive peptide hormone that is produced constitutively within the heart by vascular and endocardial endothelial cells. There is also evidence for ET-1 release by cardiac myocytes [11,12]. In addition to its vasoconstrictor action, endogenous release of the hormone is known to modulate the isotropic state of the heart and is also suggested to play a role in modulation of the heart rate (e.g. [13–16]). Elevated production and release of ET-1 is strongly implicated in the pathogenesis of heart failure and the generation of arrhythmias (for reviews see [17–19]). There is also evidence that ET-1 can be pro-arrhythmic independent of coronary vasoconstriction [12,19]. Data from patients with angina pectoris have shown left bundle-branch block to be associated with raised ET-1 levels, suggesting that the hormone may be involved in conduction abnormalities [20]. Consistent with an ability of ET-1 to exert a direct effect on the pacemaker-conduction system, experiments on cells isolated from the rabbit SAN have demonstrated that ET-1 produces a
negative chronotropic effect that is associated with direct ion channel modulation [21–23]. By contrast, to our knowledge, there is no current information available concerning direct effects of this peptide hormone on the AVN. Autoradiographic studies of the human myocardium have revealed a high density of $^{125}$I-ET-1 binding to the AVN and the penetrating and branching bundles of His, in addition to the atrial and ventricular myocardium [24]. Autoradiographic study of the porcine AVN has also demonstrated the presence of specific $^{125}$I-ET-1 binding sites in this region [25].

Indirect evidence that ET-1 can modulate AVN electrophysiology comes from electrocardiogram measurements from anaesthetised dogs and rats, which have shown that intra-coronary ET-1 administration can produce complete AV block [26,27]. Although, when considered together, the effect of intra-coronary ET-1 and evidence for presence of ET receptors in the AVN are strongly suggestive of a direct action of ET-1 on AVN electrophysiology, they are not conclusive in this regard. The present study was therefore undertaken to address this gap in information, by using an established rabbit single AVN cell preparation [6,28–32].

Materials and Methods

Ethics statement

All procedures used in these experiments were approved by the University of Bristol ethics committee and adhere to the United Kingdom Home Office Animals Scientific Procedures Act of 1986.

Rabbit AVN cell isolation

Male New-Zealand White rabbits (~2.0 to 3.5 kg) were killed in accord with UK Home Office legislation, their hearts then rapidly excised and cells isolated from the entire atrioventricular nodal (AVN) region using an established enzymatic and mechanical dispersion technique [28,29,33]. Isolated AVN cells were suspended in Kraft-Bruhe “KB” solution [28,34] and stored in a refrigerator until use.

Electrophysiological recording

For recording, cells were transferred in KB solution into an experimental chamber (0.5 ml) mounted on the stage of an inverted microscope (Nikon Diaphot) and left to settle for 10 mins prior to superfusion with a normal Tyrode’s solution, containing (in mM): NaCl 140, KCl 4, CaCl$_2$ 2, MgCl$_2$ 1, HEPES 5 and Glucose 10, (pH 7.4 with NaOH). ET-1 and other compounds were added to this solution. Patch-pipettes (Corning 7052 glass, AM Systems Inc, Sequim, WA, USA) were pulled using a P-97 Flaming/Brown micropipette puller (Sutter Instruments, Novato, CA, USA) and filled with a solution containing (in mM) [10;33]: KCl 110, NaCl 10, HEPES 10, MgCl$_2$ 0.4, and Glucose 5, K$_2$ATP dihydrate 5, GTP-Tris salt 0.5 (pH 7.1 with KOH). For ionic current but not action potential measurements the pipette solution also contained 5 mM BAPTA (cf [10,33]). Recordings were made using an Axopatch 1D amplifier (Axon Instruments; now Molecular Devices, Sunnyvale, CA, USA). Pipette resistance was typically <3 MΩ; series resistance values were usually <7 MΩ (mean of 6.07±0.68 MΩ; n=23) and ~60–80% of the series resistance was compensated. Membrane capacitance values used for calculation of current densities (pA/pF) were obtained and compensated for using capacitance compensation on the recording amplifier; cell capacitance values obtained in this way have been shown previously to match closely those obtained using a ‘surge’ technique [28]. For voltage clamp experiments, membrane potential was held at −40 mV (as this corresponds to the zero current potential for rabbit AVN cells [28,30]). Action potentials were recorded from spontaneously beating cells in current-clamp mode with zero-current injection, using a gap-free
Effects of ET-1 on AVN Cell Electrophysiology

Ai

amplitude (pA)

-400

-200

0

200

400

control

ET-1

ET-1

-40 mV

-120 mV

200 ms

Aii

amplitude (pA)

-120 mV

-100 mV

-80 mV

-60 mV

-40 mV

200 ms

B

voltage (mV)

current density (pA/pF)

-15

-10

-5

0

5

10

15

***

**

*

C

current density (pA/pF)

voltage (mV)

-120

-110

-100

-90

-80

-70

-60

-50

-40

-30

D

current density (pA/pF)

voltage (mV)

-120

-110

-100

-90

-80

-70

-60

-50

-40

-30
acquisition mode. Protocols were generated and data recorded using Clampex 8 (Axon Instruments; now Molecular Devices Sunnyvale, CA, USA). Data digitization rates were 10–25 kHz with an appropriate bandwidth of 2–10 kHz set on the amplifier.

**Results**

**Effects of ET-1 application on spontaneous APs**

Spontaneous APs were measured in whole-cell membrane potential recording mode from cells selected on the basis of exhibiting regular spontaneous activity (evidenced visually as regular spontaneous cell beating) during superfusion of control Tyrode’s solution. Figure 1A shows a representative slow time-base record of APs, before, during and following exposure to 10 nM ET-1, whilst Figures 1Bi–iii show faster time-base extracts at the time-points indicated on Figure 1A. The mean spontaneous AP rate in control solution was 3.47 ± 0.53 AP s⁻¹ (n = 9), compatible with rates seen in previous studies [10,28,31,33]. Application of ET-1 led rapidly to membrane potential hyperpolarisation and to cessation of spontaneous APs (within 13.1 ± 2.1 s of ET-1 application; n = 9). As shown in Figure 1A, after reaching an initial peak response (the mean peak membrane potential hyperpolarisation produced by ET-1 in comparison to control maximum diastolic potential values was −20.3 ± 2.0 mV, n = 9), membrane potential showed gradual depolarisation but without a return of spontaneous activity. As has been reported in some other studies (e.g. [21,39]), the effect of ET-1 was not reversible on washout and membrane potential continued to show modest membrane potential depolarisation throughout the remainder of the measurement period. In all cells, whilst on ET-1 application cells rapidly ceased to generate spontaneous APs, small membrane potential oscillations were visible (mean amplitude 5.5 ± 0.3 mV, n = 9 cells; more than 25 oscillations analysed per cell), with occasional oscillations exceeding 10 mV; see Figures 1Ai and 1Bi and iii).

**Effects of ET-1 on ionic currents at negative membrane potentials**

AVN cell sub-types exhibiting time-independent and time-dependent current (I₉) on membrane potential hyperpolarisation in standard extracellular solution have been identified [29,31]. The effects of ET-1 were determined on cells with both response types. Effects of ET-1 were determined by application of 500 ms duration hyperpolarising voltage clamp commands: from a holding potential of −40 mV membrane potential was stepped to more negative potentials between −120 and −40 mV in 10 mV increments (at a pulse frequency of 0.2 Hz). Figure 2Ai shows current records elicited on membrane potential hyperpolarisation to −120 mV, for a cell that exhibited only time-independent current in control solution. On the application of ET-1, holding current shifted outwards (in control, holding current at −40 mV was −0.4 ± 0.3 pA/pF, n = 7, NSD from zero current; in ET-1 this became 1.1 ± 0.4 pA/pF; p < 0.001 versus control). At −120 mV a large inward current was induced, with a marked increase in instantaneous inward current. Some time-dependence of the current can be seen in this example. Figure 2Aii shows ET-1 sensitive (activated) current from the same cell, at −90, −100 and −120 mV. Outward holding current is visible prior to the marked inward current elicited on membrane potential hyperpolarisation, the amplitude of which increased progressively with the magnitude

---

**Figure 2. Modulation by ET-1 of instantaneous current in cells lacking I₉.**

Ai. Currents recorded in the absence (control) and the presence of 10 nM ET-1 at −120 mV (upper traces) when a voltage command was applied from −40 mV for 500 ms (lower trace). Note outward shift in holding current with ET-1. Closed circles indicate control trace; open circles indicate trace in ET-1. All ET-1 activated currents (elicited at −90, −100 and −120 mV) obtained by digital subtraction of control from ET-1 records (same cell as Ai). B. Mean current-voltage (I–V) relationships for current measured at the start of applied voltage commands in absence (control, filled circles) and presence (open circles) of 10 nM ET-1 (n = 7). Asterisks denote statistical significance (p < 0.05 *, p < 0.01 **, p < 0.001 ***). C. Plot of the mean I–V, relationship for ET-1 sensitive difference (ET-1 activated) calculated from the same cells shown in B. D. Plot of ET-1 sensitive current when ET-1 was applied after 1 µM BQ-123 (n = 4).

doi:10.1371/journal.pone.0033448.g002
Figure 3. ET-1 effects on the hyperpolarisation-activated current $I_h$.

A. Upper traces show currents elicited $-120$ mV in an $I_h$-expressing cell in control solution and 10 nM ET-1 by protocol shown in bottom trace. Note outward shift in holding current in presence of ET-1. Closed circles indicate control trace; open circles indicate trace in ET-1.

B. Mean I–V relationships ($n = 7$) for $I_h$, plotted as time-dependent current during command pulses, in absence (control, filled circles) and presence of 10 nM ET-1 (open circles). The activating effect of ET-1 was significant only at $-120, -110$
of the applied hyperpolarising step. The stimulatory effect of ET-1 in augmenting time-independent (instantaneous) current was quantified by plotting current density-voltage relations for instantaneous current in control and in ET-1 (Figure 2B) and also by deriving from individual experiments the ET-1 sensitive difference (ET-1 activated) current, the mean of which is plotted in Figure 2C. Net instantaneous current (Figure 2B) was augmented by ET-1 across a range of potentials, with a leftward shifted zero-current potential compared to control; control and ET-1 current-voltage relations intersected near −80 mV (Figure 2B). The ET-1 activated current (Figure 2C) showed marked inward rectification and reversed at ∼−82 mV (with a mean reversal potential derived from individual cell data of −82.1±1.2 mV; n = 7). The activation of this current accounts for the leftward shift in zero current potential for net instantaneous current visible in Figure 2B. The ET-1 activated current was outwardly directed over potentials relevant to the diastolic potential range (typically between −65 and −40 mV). The ET-1 response showed some time-dependent ‘fade’ in the continued presence of the peptide: the mean amplitude of the ET-1 activated current at −120 mV immediately following (within 10–20 s) of ET-1 application was −7.2±0.7 pA/pF (n = 7), whilst at −2 s minutes following ET-1 this had declined to −1.7±0.3 pA/pF (n = 7; p<0.001 versus immediate response) and in two cells that lasted ∼3.5 minutes following ET-1 this was −0.6±0.2 pA/pF. In cells pre-treated with BQ-123, ET-1 did not activate such a current: Figure 2D shows the instantaneous ET-1 sensitive difference current in cells exposed to BQ-123 prior to ET-1 application. This implicates ETA receptor activation in the observed response.

Figure 3 shows comparable data for cells that exhibited If in control. Figure 3A shows representative currents in control solution and in the presence of ET-1. A dual effect was seen, in which both instantaneous and time-dependent current components were augmented in the presence of ET-1. Previously, If from AVN cells has been measured as the difference between end-pulse current and instantaneous current observed at the start of the hyperpolarising step [29,33] and this method was used here to produce the mean I–V relations shown in Figure 3B. As reported previously [29,33], under these conditions there was little If between −60 and −80 mV in control Tyrode’s solution, whilst significant If was evident at more negative voltages. In the presence of ET-1, time-dependent current was significantly augmented at potentials of −100 mV and more negative than this (Figure 3B). However, this response was transient: the mean amplitude of If at −120 mV immediately following (within 10–20 s) of ET-1 was −4.3±0.6 pA/pF (n = 7), whilst at −2 minutes following ET-1 this was −1.9±0.7 pA/pF (n = 7; p<0.001 versus the immediate response), with the current at ∼3.5 minutes following ET-1 similar to that following 2 minutes of exposure. Figures 3G and 3I show effects of ET-1 on the instantaneous current component (i.e. comparable data to those shown in Figures 2B and 2C), demonstrating that activation of an inwardly rectifying instantaneous current also occurred in these cells. Figure 3G shows mean net instantaneous current in control and ET-1, again showing a leftward shift in zero-current potential and intersection of the two relations close to −80 mV. Figure 3I shows the current-density plot for ET-1 activated current, which resembles that in Figure 2C. Note that the magnitude of the ET-1 activated current was not significantly different from that from cells that lacked If, except at −120 mV (p<0.01 at this potential only). Figure 3D shows plots of time-dependent If in the presence of BQ-123 and BQ-123+ET-1. These were closely superimposed, implicating ETA receptors in the effect of ET-1 on If. Figure 3E shows that, similar to cells lacking If (Figure 2), ET-1 failed to activate instantaneous inwardly rectifying current in the presence of BQ-123.

Effects of ET-1 on I\textsubscript{Ca,L}

Similar to other recent studies from our laboratories [10,33], the effects of ET-1 on I\textsubscript{Ca,L} were determined from currents measured over a range of test potentials (500 ms commands were applied to voltages between −30 and +50 mV from a holding potential of −40 mV). Figure 4A shows representative traces of I\textsubscript{Ca,L} elicited by depolarisation from −40 mV to +10 mV in the absence and presence of ET-1, showing a marked suppression of peak current amplitude by ET-1. Figure 4B shows mean current-voltage relations for I\textsubscript{Ca,L} in control and with ET-1. Repeated applications of the I\textsubscript{Ca,L} measurement protocol in the presence of ET-1 did not lead to significant further reductions in current beyond that shown in Figure 4A. A fit to the data with equation 1 yielded an activation V\textsubscript{0.5} of −2.7±0.6 mV in control and of −1.0±1.9 mV in ET-1 (n = 11 cells; p<0.01), whilst G\textsubscript{max} values derived from the fits to the data were 0.36±0.03 nS/pF (control) and 0.16±0.03 nS/pF (ET-1; p<0.001). In 12 further experiments, cells were exposed to the ETA receptor antagonist BQ-123 (1 μM) prior to ET-1 application. Figure 4C shows mean I–V relations from these experiments: with BQ-123 application prior to ET-1 superfusion, ET-1 did not reduce I\textsubscript{Ca,L} amplitude at any membrane voltage, implicating ETA receptor activation in this action of ET-1. In 6 cells in which I\textsubscript{Ca,L} at +20 mV was monitored during ET-1 exposure and following washout, the inhibitory effect of ET-1 was not reversed by washout.

Effects of ET-1 on rapid delayed rectifier K\textsuperscript{+} current, I\textsubscript{Kr}

The rapid delayed rectifier K\textsuperscript{+} current, I\textsubscript{Kr}, is important to AVN AP repolarisation and can also influence spontaneous rate [33,40–42]. I\textsubscript{Kr} is typically measured from AVN cells as outward tail current on repolarisation to a negative voltage following depolarising voltage commands, and lacks contamination from potentially overlapping currents such as If, which is absent from rabbit AVN cells [33,41–44]. Accordingly, the effects of ET-1 on I\textsubscript{Kr} were assessed by measurements of outward tail current amplitude at −40 mV, following 500 ms voltage commands to more positive potentials (between −30 and +50 mV). Figure 5A shows representative traces elicited following depolarisation to +30 mV in the absence and presence of ET-1, with the inset displaying the tails currents on a higher gain. ET-1 produced a 20–30% decrease in tail current amplitude. Figure 5B shows mean I–V relations for I\textsubscript{Kr} tails in control and at steady-state in ET-1 (n = 5). Tail currents were significantly reduced at nearly all potentials between −20 and +50 mV. A fit to the data with equation 2 yielded activation V\textsubscript{0.5} values of −15.7±3.6 and −0.7±4.3 mV in control and ET-1 respectively (p<0.05; n = 5).
Figure 4. Effects of ET-1 on the L-type Ca^{2+} current (I_{Ca,L}). A. Representative records of $I_{Ca,L}$ (upper traces) elicited at +10 mV from a holding potential of −40 mV by protocol shown in lower traces, in both the absence (control) and presence of 10 nM ET-1. B. Plots of the mean I–V relations for $I_{Ca,L}$ (n = 11), measured as peak - end pulse difference current, in control (filled circles) and with ET-1 (open circles): I–V curves were fitted using...
Figure 5C shows mean tail current I–V relations for five experiments on cells exposed to BQ-123 prior to ET-1. There was no significant difference between BQ-123 alone and ET-1 in the presence of BQ-123 in tail current at any test voltage, implicating ET_A receptor activation in mediating the suppressive effect of ET-1 on I_Kr tail amplitude. Although ET-1 was applied in the presence of BQ-123 still appeared to produce some right-ward shift in the fit to the current-voltage relationship (V_{0.5} of -12.0±5.1 mV in BQ-123 alone and -2.9±6.4 mV in BQ-123 and ET-1; n = 5), due to cell-to-cell variability in response the difference did not attain statistical significance (p > 0.3). Similar to I_{Ca,L} the effects of ET-1 on I_Kr did not reverse on ET-1 washout.

Investigation of the mechanism of AP quiescence

The rapid membrane potential hyperpolarisation with ET-1 during spontaneous AP recording shown in Figure 1 is consistent with the activation of an outward current over the diastolic membrane potential range. The ET-1 activated current observed here (Figures 2 and 3) exhibited a voltage dependence reminiscent of inwardly rectifying K_+ current in AVN cells activated by acetylcholine (I_{K,ACh}) or adenosine (I_{K,Ado}) each of which exert marked negative chronotropic effects on isolated AVN cells (e.g. [28,30]). Tertiapin/tertiapin-Q have been shown previously to inhibit sinoatrial I_{K,ACh} (e.g. [45,46]) and to inhibit atrio-ventricular block induced in the guinea-pig by I_{K,Ado} activation [47]. We hypothesised, therefore, that if ET-1 activates a current similar to I_{K,ACh} in AVN cells, tertiapin-Q should prevent rapid ET-1 induced membrane potential hyperpolarisation and hyperpolarisation-associated cell quiescence. Consequently, experiments were performed in which tertiapin-Q was applied prior to ET-1 superfusion during spontaneous AP recording. Figure 6A shows representative results. Application of 300 nM tertiapin-Q alone did not alter spontaneous activity; however when ET-1 was subsequently applied in the maintained presence of tertiapin-Q, no rapid MDP hyperpolarisation or hyperpolarisation-associated quiescence was induced. Instead, there was a gradual depolarisation of MDP and decrease in AP amplitude (this cell depolarised and became quiescent within ~30 seconds of ET-1 in the presence of tertiapin-Q). Similar experiments were performed on seven spontaneously active cells; in none of them did ET-1 induce membrane potential hyperpolarisation in the presence of tertiapin-Q. Experiments were then performed to determine whether or not tertiapin-Q also inhibited ET-1 activated current under voltage clamp. Figure 6C shows that, in the presence of tertiapin-Q, ET-1 was unable to activate any inwardly rectifying instantaneous current. In a further 7 experiments, a second known inhibitor of inwardly rectifying ACh-activated K_+ conductances, Ba^{2+} ions, was applied (at 2 mM; [48]) during repetitive application of a descending voltage-ramp protocol. Ba^{2+} rapidly inhibited the ET-1 activated current in all cells tested (not shown). Collectively, the results of these experiments implicate ET-1 activation of an I_{K,Ado}-like current in the rapid suppression of spontaneous activity shown in Figure 1.

ET-1 effects on all currents observed under voltage-clamp were sensitive to ET_A receptor inhibition (Figures 2, 3, 4, and 5). Therefore, additional spontaneous AP recordings were performed in which the ET_A receptor inhibitor BQ-123 was applied prior to ET-1 superfusion. Figure 7 shows the results from one of six similar experiments. When ET-1 was applied following exposure of cells to BQ-123 no rapid membrane potential hyperpolarisation or suppression of spontaneous activity was observed. In a final set of experiments, the effects of a selective ET_B receptor agonist, IRL-1620 were investigated. IRL-1620 produced a small depolarisation of MDP (by 5.2±1.4 mV; n = 3) and became in AP overshoot (a mean reduction of 14.1±1.4 mV; see Figure 8); however, no cell tested responded to IRL-1620 with membrane potential hyperpolarisation or quiescence. In contrast, when ET-1 was applied in the maintained presence of IRL-1620 it produced rapid membrane potential hyperpolarisation and quiescence (similar to that seen when ET-1 alone was applied; Figure 1).

**Discussion**

**Placing novel findings in context**

To our knowledge, the present data are the first to demonstrate directly modulation by ET-1 of AVN electrophysiology. Previously, intravenous administration of BQ-123 to anaesthetised pigs and, via intracoronary injection, to a small sample of human patients with coronary artery disease has been reported not to alter AV nodal conduction [49,50], suggestive of a lack of effect of basal endogeneous ET-1 on AV nodal conduction via ETA receptors in those studies. On the other hand, intracoronary bolus injection of ET-1 to anaesthetized dogs [26,27] and rats [26,27] has been shown to produce AV block, which is suggestive of an ability of increased ET-1 levels to modulate AVN electrical behaviour. The results of the present study show that ET-1 can suppress AVN cell activity, and the modulatory effects on AVN cellular electrophysiology seen here may help explain prior observations of ET-1 induced AV block [26,27]. This is also the first study to demonstrate tertiapin-Q sensitivity of an ET-1 activated K_+ current in any cell or tissue type. Several features of our findings merit more detailed discussion.

**Comparison with previous studies**

Whilst the effects of ET-1 on cardiac ion channel currents from other cardiac cell types have been widely studied, the most relevant data for comparison with the present study come from prior investigations of isolated sinoatrial node (SAN) cell and tissue preparations [21–23]. In 2001 Ono and colleagues demonstrated negative chronotropic effects of ET-1 on rabbit intact SAN preparations and isolated SAN cells [23]. Application of ET-1 at the same concentration used in the present study (10 nM) was able to induce quiescence in isolated SAN cells, which either did not readily reverse or reversed incompletely during the recording measurement period. However, the negative chronotropic effect of ET-1 seen in that study was accompanied by membrane potential hyperpolarisation only in some (rod-shaped) cells, whilst other (spindle-shaped) cells showed depolarisation of the MDP [23]. A separate study of rabbit SAN cells by Tanaka and colleagues produced results in good agreement with those in the present investigation: application of 10 nM ET-1 routinely led rapidly to cessation of spontaneous activity and to membrane potential hyperpolarisation [21]. In the present study, all spontaneously active AVN cells exposed to ET-1 exhibited rapid membrane...
Figure 5. Effects of ET-1 on rapid delayed rectifier $K^+$ current tails. A. Upper traces show currents elicited on depolarisation to $+30 \text{ mV}$ and subsequent repolarization to $-40 \text{ mV}$ by protocol shown in lower trace. Deactivating tail currents on repolarization represent the $I_{Ks}$ ‘tail’. Currents are shown in control solution and in presence of 10 nM ET-1. Insert shows an expanded portion of the traces to highlight the ‘tail’ currents (the horizontal arrow in the inset denotes the zero current level). B. Mean ‘tail’ current $I-V$ relationships for 5 cells, in absence (control, filled circles) and
presence (open circles) of 10 nM ET-1. I–V curves were fitted with equation 2 (Methods) to derive $V_{0.5}$ values of $-15.7 \pm 3.6$ mV in control and $-0.7 \pm 4.3$ mV in ET-1 (p<0.05), with respective k values of $6.4 \pm 2.6$ mV and $6.9 \pm 3.9$ mV (p<0.9). The ‘tail’ current was significantly reduced in presence of ET-1 at all voltages ranging from $-20$ to $+50$ mV except $+20$ mV. C. Mean I–V plots for $I_{\alpha}$ tails in the presence of 1 $\mu$M BQ-123 without (filled squares; n = 5) and with 10 nM ET-1 (open squares, n = 5 for all, except at $+40$ and $+50$ mV where n = 4). Derived $V_{0.5}$ values were $-12.0 \pm 5.1$ mV and $-2.9 \pm 6.4$ mV for BQ-123 and BQ-123+ET-1, respectively (p<0.3), with associated k values of $4.9 \pm 4.4$ and $8.4 \pm 5.8$ (p<0.6).

Figure 6. Effects of tertiapin-Q (TQ) on the effect of ET-1 on spontaneous APs and ET-1 activated current. A. Continuous recording of spontaneous activity in control, in the presence of TQ (300 nM) before and with application of 10 nM ET-1 in the maintained presence of TQ. Note the absence of immediate hyperpolarisation and cessation of APs evident in Figure 1. Bi, ii and iii show expanded records from recording in A, at time-points indicated: i taken during control, ii near the end of TQ alone and iii is taken at $-13$ seconds of ET-1 application (at which time-point cells exposed to ET-1 alone had hyperpolarised and become quiescent). Similar results were obtained from 7 cells. C. Mean I–V relationships for the 10 nM ET-1 activated instantaneous current in absence (filled triangles, n = 14) and in presence of 300 nM TQ (open triangles, n = 7. except at $-80$ mV where n = 6). TQ prevented this action of ET-1. Asterisks in C denote statistical significance (p<0.05 *, p<0.001 ***).

doi:10.1371/journal.pone.0033448.g006
potential hyperpolarisation and quiescence. Voltage-clamp data from both SAN studies indicated a marked inhibitory action of ET-1 on ICa,L (50% inhibition at 10 nM ET-1) which is in reasonable agreement with our own observations for AVN cells. This contrasts with more modest effects of ET-1 on guinea-pig ventricular ICa,L (21% inhibition of basal ICa,L by 20 nM ET-1 [51] and human ventricular ICa,L (~33% inhibition of basal ICa,L by 8 nM ET-1 [52]). Such differences may be accounted for by regional and/or species differences in ET-1 response, with rabbit primary and secondary pacemaker cell types exhibiting a greater response than ventricular myocytes from these two other species. The possibility of regional differences in response is supported by results from a study of rabbit ventricular myocytes [36] that reported weak bi-phasic effects of 10 nM ET-1 on basal ICa,L, with an inhibitory effect of smaller magnitude (~20%) than those seen for AVN (this study) or SAN [21,23]. Ono and colleagues also reported that 10 nM ET-1 activated If between ~275 and ~285 mV, but that it inhibited If at more negative voltages [23]; Tanaka and colleagues also reported an inhibitory action [22]. On the other hand, we saw significant augmentation of AVN cell If by ET-1, but only at potentials negative to the diastolic potential range. Similar to previous studies conducted under comparable recording conditions [29,33], If from AVN cells under control conditions here was small or absent over the diastolic potential range and the lack of any statistically significant effect of ET-1 at potentials positive to ~2100 mV makes it unlikely that modulation of If by ET-1 contributed significantly to effects seen under AP recording conditions. By contrast, the activation of an inwardly rectifying K+ current, with significant ET-1 activated outward current between ~240 and ~280 mV is of central importance to the overall actions of ET-1 seen here. The ability of ET-1 to activate a current with similar properties to the muscarinic potassium current (IK,ACh) was first demonstrated for non-pacemaker cardiac cells [54,55], although some studies have demonstrated an ability of ET-1 to inhibit IK,ACh and IK,Ado (e.g. [56–58]). Tanaka and colleagues demonstrated activation by ET-1 in rabbit SAN cells of an inwardly rectifying K+ current similar to that seen here, also showing this to be Ba2+-sensitive and to carry outward current over potentials relevant to the diastolic potential range [21]. Drici and colleagues have demonstrated that ACh-induced AV block in guinea-pig hearts is prevented by tertiapin at...
concentrations including that used here, without non-selective effects of tertiapin on other important cardiac ionic currents [47]. Thus, the inhibition by tertiapin-Q of the ET-1 activated (Ba\(^{2+}\)-sensitive) inwardly rectifying current in AVN cells seen here identifies the underlying channels as similar to those that mediate IK,ACh. It is also notable that activation of a similar K\(^{+}\) current (IK,Ado) contributes significantly to the known negative chronotropic and dromotropic effects of adenosine [30,59]. Moreover, it is evident from the complete lack of membrane potential hyperpolarisation when ET-1 was applied to cells treated with tertiapin-Q, that this current mediated the rapid hyperpolarisation and quiescence of AVN cells following ET-1 application. IK,ACh from the SAN has been shown to exhibit a time-dependent fade in the presence of continued muscarinic receptor activation as a result of desensitization [60,61] and our results indicate that a similar phenomenon occurs for ET-1 activated inwardly rectifying K\(^{+}\) current in AVN cells. The mechanism underlying this effect remains to be elucidated and warrants future study. The progressive MDP depolarisation and decrease in AP amplitude seen when ET-1 was applied to tertiapin-Q treated cells can be explained, wholly or in part, by ET-1 inhibition of IKr (which would predispose towards membrane potential depolarisation) and of ICa,L (which would decrease AP amplitude and may also offset AP prolongation anticipated with pure IKr inhibition), neither of which response showed time-dependent fade. Similarly, the persistence of an ET-1 effect following ET-1 washout, namely maintained quiescence and progressive membrane potential depolarisation (Figure 1), can be accounted for by continued ET-1 receptor activation following washout and by the peptide’s effects on IKr/ICa,L predominating as the inwardly rectifying current response became desensitized/faded. Our data in this regard are compatible with previously reported quasi-irreversible binding of ET-1 to cardiac myocytes ET (ETA) receptors and on ET-receptor mediated signalling [39].

A central role for ETA receptors

 Autoradiographical examination of the human cardiac conduction system has demonstrated the presence of both ETA and ETB receptors in the AVN and atrio-ventricular conduction system [24], with a higher proportion of ETB receptors and lower proportion of ETA receptors in the AV conduction system than in the surrounding interventricular and interatrial septa [24]. mRNA for both ET
receptor types has been demonstrated to be widespread in the rabbit heart [23], with mRNA levels for ET₂ in the SAN suggested to be similar to those in atria and ventricles, whilst those for ET₁ have been reported to be highly sensitive to ET₁ receptor blockade [21,23]. Inhibitory effects of ET-1 on SAN action potentials and ionic currents have been replicated to be highly sensitive to ET₁ receptor blockade [21,23]. Inhibitory effects of ET-1 on SAN ICa,L and IK and the activation of IK,ACh-like inward rectifier current were all abolished by selective ET₁ blockade [21]. Our data provide strong evidence for a similar pivotal role for ET₁ receptor involvement in ET-1 modulation of AVN cell activity, both at the level of effects on spontaneous APs and also for ionic currents. It is particularly notable that application of the ET₁-selective agonist IRL-1620 led rapidly to these effects. This indicates that the dominant, rapid-onset effect of ET-1 under our conditions was activation of tertiapin-Q sensitive IK,ACh-like current, mediated through ET₁ receptors. Our data do not preclude entirely potential roles for ET₁ receptor activation: application of IRL-1620 itself led to a modest reduction in AP magnitude and, under voltage-clamp, of ICa,L (data not shown). Whether or not these actions of IRL-1620 are mediated through ET₁ receptor activation per se or represent a non-selective action of this agent is unclear at this time. Efforts to pursue this line further through the use of a selective ET₁ receptor antagonist, RES-701, were confounded by potential contaminating effects that led us to abandon its use. Nevertheless, what is very clear from our experiments is the dominant role played by ET₁ receptor activation in the observed effects of ET-1, which is in good agreement with prior work on the SAN.

Limitations, future work and conclusions
Understanding of the cellular electrophysiology of the AVN and its modulation has tended to lag behind that of other cardiac regions, to a significant extent likely due to challenges inherent in isolating and working with single AVN cells. Accordingly, the present study is the first to characterise major actions of ET-1 on AVN APs and ionic currents and has identified a number of marked effects. However, whilst our voltage-clamp data can account for the principal effects of ET-1 seen on spontaneous AVN APs, this does not mean that the basis for all modulatory effects have yet been identified. For example, the underlying basis for the small amplitude spontaneous membrane potential oscillations in quiescent AVN cells following ET-1 treatment (Figure 1) remains to be elucidated. Recent data indicate that AVN activity is influenced by cellular Ca²⁺ cycling, likely through the interaction between Ca²⁺ released from internal stores and the sarcolemmal Na-Ca exchanger (NCX) [10,62,63]. ET-1 has been reported to stimulate NCX activity [64,65] and the effects of ET-1 on AVN NCX remain to be investigated. Additionally, it is well established that in atrial myocytes ET-receptor activation of IP₃ receptors can influence Ca²⁺ mobilization (e.g. [66–68]) and IP₃ receptor activity has recently been proposed to modulate murine SAN activity [69]. Thus, potential additional effects of ET-1 on AVN activity mediated by the modulation of Ca²⁺ handling merits future enquiry. The experimental concentration of ET-1 used in this study (10 nM) lies within the range used in previous rabbit SAN and ventricular cardiomyocyte studies (1–100 nM; e.g. [21,23,36]) and is similar to that (8 nM) used to study ET-1 effects on undiseased human ventricular myocytes [52]. It should be noted that, whilst normal plasma levels of ET-1 are low (in the fM-pM range; e.g. [70,71]), considerably higher pericardial and tissue levels can be measured (e.g. [71,72]). We are not aware of data on endogenous ET-1 levels in AVN tissue per se, but a level of ~1.2 nM has been measured in rabbit left ventricle [71], whilst in human atrial tissue a mean level of ~19 nM (range ~2–64 nM) has been measured [72]. Thus, whilst the ET-1 concentration used in this (and other) studies is likely to exceed circulating plasma levels, it lies within measured cardiac tissue levels [71,72]. Additional avenues of future investigation opened by the present report include the determination of effects of wide-ranging ET-1 concentrations (cf. [21]), the study of intracellular pathways mediating major identified effects, and investigation of effects of ET-1 on autonomic agonist modulation of AVN activity.

To summarise and conclude: the present study demonstrates for the first time that ET-1 activation of ET₁ receptors produces a rapid suppression of spontaneous activity of rabbit AVN cells. ET₁ also inhibits both IK₃ and ICa,L from AVN cells whilst activating K⁺ current through channels identical to those responsible for muscarinic inwardly rectifying K⁺ current. This current mediates the initial rapid hyperpolarisation and quiescence produced by ET₁, whilst IK₃ and ICa,L suppression are likely to contribute to maintained suppression of excitability. Bolus injection of ET-1 in previous experimental studies on anaesthetised animals [26,27] is likely to have produced a rapid, local rise in ET-1 in blood perfusing the AVN. Rapid membrane potential hyperpolarisation through activation of an IK,ACh-like current and suppression of currents important to AVN AP genesis can account for the AV block subsequently observed in those studies [26,27] - a proposition that can be tested further through future targeted experiments using intact AVN preparations.

Acknowledgments
The authors thank Mrs Lesley Arbery for technical assistance, Dr Palash Barman and Ms Hanne Gadeberg for help with cell isolation, Prof Clive Orchard for valuable discussion and encouragement, and Dr Antony Workman (Glasgow) for valuable discussion.

Author Contributions
Conceived and designed the experiments: JCH AFJ SCMC. Performed the experiments: SCMC HWC. Analyzed the data: SCMC HWC. Wrote the paper: JCH AFJ SCMC. Involved in original design of the study and edited/commented on a completed form of the manuscript: GLS.

References
1. Tawara S (1990) Das Reizleitungssystem des Saugtierherzens. 1 ed. Jena, Germany: Fischer.
2. Meijler FL, Janse MJ (1988) Morphology and electrophysiology of the mammalian atrioventricular node. Physiol Rev 68: 608–47.
3. Anderson RH, Janse MJ, van Capelle FJL, Bilette J, Becker AE, et al. (1974) A mathematical model of the atrioventricular node including atrio-nodal, nodal, and nodal-his cells. Biophys J 7: 791–799.
4. Langendorf R, Pick A (1956) Concealed conduction. Further evaluation of a paper: JCH AFJ SCMC. Involved in original design of the study and edited/commented on a completed form of the manuscript: GLS.
10. Cheng H, Smith GL, Hancox JC (1998) Inhibition of spontaneous activity of rabbit atrioventricular node cells by KB-R7943 and inhibitors of sarcoplasmic reticulum Ca++ ATPase. Cell Calcium 26: 56-63.

11. Rubanyi GM, Pollock MA (1994) Endothelins: molecular biology, biochemistry, pharmacology and pathophysiology. Pharmac Res 6: 325-415.

12. Russell FD, Molenaar P (2000) The human endothelin system: ET-1 synthesis, storage, release and effect. TIPS 21: 353-359.

13. Mebazaa A, Mayoux E, Maela K, Martin LD, Lakatta EG, et al. (1993) Perfusion effects of endothelin-1 on epicardial endocardial cells on myocyte conctractile via mediated endothelins. Am J Physiol 265: H1041–H1046.

14. MacCarthy PA, Groccott-Mason R, Prendergast BD, Shah AM (2000) Contrasting inotropic effects of endogenous endothelins in the normal and failing human heart studies with an intracoronary ET(A) receptor antagonist. Circulation 101: 142-147.

15. Wenzel RR, Fleisch M, Shaw S, Noll G, Kaufmann U, et al. (1998) Hemodynamic and coroarary effects of the endothelin antagonist Bosentan in patients with coronary artery disease. Circulation 90: 2235-2240.

16. Sutsch G, Biering-Sorensen F, Koch-Weser J (1997) Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist Bosentan in humans. Cardiovasc Drugs Ther 10: 717-725.

17. Duru F, Barton M, Loecher TP, Canadins R (2001) Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs? Cardiovasc Res 47: 272-280.

18. Kawanabe Y, Nauli SM (2011) Endothelin. Cell Mol Life Sci 68: 195–203.

19. Wainwright CL, McCabe C, Kane KA (2005) Endothelin and the ischaemic heart in vivo. Circulation 112: 2165–2176.

20. Takana H, Habuchi Y, Nishio M, Yamamoto T, Suto F, et al. (1998) Negative chronotropic actions of endothelin-1 on rabbit sinoatrial node pacemaker cells. Br J Pharmacol 122: 321-329.

21. Tanaka H, Habuchi Y, Yamamoto T, Nishio M, Morikawa J, et al. (1997) Comparison of the hyperpolarisation-induced and delayed rectifier currents in rabbit atrioventricular node cells. J Cardiovasc Pharmacol 31(S1): S440–S442.

22. Ono K, Masumiya H, Sakamoto A, Christe G, Shijuku T, et al. (2001) Electrophysiological study of the negative chronotropic effect of endothelin-1 in rabbit sinoatrial node cells. J Physiol 537: 463–481.

23. Molenaar P, O'Reilly G, Sharkey A, Kuk RE, Harding DP, et al. (1993) Hemodynamic and coronary effects of the endothelin antagonist Bosentan in patients with coronary artery disease. Circulation 90: 679-683.

24. Tanaka H, Habuchi Y, Yamamoto T, Nishio M, Morikawa J, et al. (1997) Negative chronotropic actions of endothelin-1 on rabbit sinoatrial node pacemaker cells. Br J Pharmacol 122: 321-329.

25. Watanabe T, Endoh M (1999) Characterization of the endothelin-1 induced regulation of L-type Ca current in rabbit ventricular myocytes. Naunyn-Schmiedeberg's Arch Pharmacol 360: 654-664.

26. Isenberg G, Klockner U (1982) Calcium tolerant ventricular myocytes prepared from rabbit sinoatrial node cells. J Physiol 332: 463-485.

27. LeNer M, Leibovitch E, Preminger S, Yardeni Y, Dizengoff M, et al. (1997) Inhibition of spontaneous action potentials in rabbit atrioventricular node myocytes by diltiazem. J Cardiovasc Pharmacol 29(S1): S440–S442.

28. Ishikawa K, Otsuka T, Ueda T, Ogasawara M, Kitaoka M, et al. (2001) Role of endothelin-A receptor in rat atrioventricular node cells. J Cardiovasc Pharmacol 38(S1): S440–S442.

29. Kolettis TM, Kyriakides ZS, Leftheriotis D, Papalambrou A, Kremastinos DT, et al. (2005) Electrophysiological effects of endothelin receptor-A blockade in patients with coronary artery disease. J Interv Card Electrophysiol 8: 173-179.

30. Xie LH, Horie M, James AF, Watanuki M, Sasayama S (1996) Endothelin-1 inhibits L-type Ca currents enhanced by isoproterenol in guinea-pig ventricular myocytes. Pflugers Arch 431: 335-339.

31. Mou J, Mollard C, Panneville A, Tanguy M, Virag L, et al. (2000) Effects of endothelin-1 and calcium currents in undeseased human atrial ventricular myocytes. Pflugers Arch 441: 149-154.

32. Lei M, Cooper PJ, Cammell P, Koff P (2002) Role of the 293B-sensitive, slowly activating delayed rectifier potassium current, Ik, in pacemaker activity of rabbit isolated sino-atrial node cells. Cardiovasc Res 53: 68-79.

33. Kim D (1991) Endothelin activation of an inwardly rectifying K+ current in atrial cells. Circ Res 69: 250-253.

34. Ohno K, Tsujimoto G, Sakamoto A, Eto K, Masaki T, et al. (1994) Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature 370: 301-304.

35. Spier JS, Kelso EJ, McDermott BJ, Scholfield CN, Silke B (1996) Endothelin-1 mediated inhibition of the acetycholine-activated GIRQK channels by G-coupled receptors in mouse atrial myocytes. Korean J Physiol Pharmacol 14: 1085-1088.

36. Suganuma M (1990) Regulation of Na+ channels in cultured rat atrioventricular node myocytes. Am J Physiol 258: H755–H766.

37. Langer K, Roux F, Watanabe T, Endoh M (1999) Characterization of the endothelin-1 induced regulation of L-type Ca current in rabbit ventricular myocytes. Naunyn-Schmiedeberg's Arch Pharmacol 360: 654-664.

38. Ibara M, Noguchi K, Sasaki T, Fukuzora T, Tsuchida S, et al. (2002) Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 70: 247-253.

39. Takai M, Umemura I, Yamaksa K, Watakabe K, Fujitani Y, et al. (1992) A potent and specific agonist, Suc[Gllo9,Ala11,15]-endothelin-1(8–21), IRL 1620, for the ETa receptor. Biochem Biophys Res Commun 186: 953-959.
Effects of ET-1 on AVN Cell Electrophysiology

68. Mackenzie L, Roderick HL, Berridge MJ, Conway SJ, Bootman MD (2004) The spatial pattern of atrial cardiomyocyte calcium signalling modulates contraction. J Cell Sci 117: 6327–6337.

69. Ju YK, Liu J, Lee BH, Lai D, Woodcock EA, et al. (2011) Distribution and functional role of inositol 1,4,5-trisphosphate receptors in mouse sinoatrial node. Circ Res 109: 848–857.

70. Mitani H, Takimoto M, Bandoh T, Kinura M (2000) Increases in vascular endothelin-converting enzyme activity and endothelin-1 level on atherosclerotic lesions in hyperlipidemic rabbits. Eur J Pharmacol 387: 313–319.

71. Löffler B-M, Roux S, Kalina B, Clozel M, Clozel J-P (1993) Influence of congestive heart failure on endothelin levels and receptors in rabbits. J Mol Cell Cardiol 24: 407–416.

72. Horkay F, Laine M, Szokodi I, Leppaluoto J, Vuolteenaho O, et al. (1995) Human pericardial fluid contains the highest amount of endothelin-1 of all mammalian biologic fluids thus far tested. J Cardiovasc Pharmacol 26: S502–S504.